CHAMBERSBURG, Pa. – The interventional cardiology team at Chambersburg Hospital recently became the first in the region to offer patients with coronary artery disease a new treatment option that literally disappears over time.
Dr. Arshad Safi and Dr. Aylmer Tang, Interventional Cardiologists, Chambersburg Hospital, have been offering the technology, which is the world's first FDA-approved dissolving heart stent, to suitable patients since November 17, 2016. The Absorb bioresorbable vascular scaffold is a major advance in the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide despite decades of therapeutic advances.
“We are thrilled to be able to offer our patients the latest technologies available for their care,” Dr. Safi explained. “Often, there is a misconception that rural hospitals cannot offer their patients these types of options, and that’s simply untrue. We continue to offer leading-edge care to our patients, from the convenience of their hometown hospital, which is our greatest honor.”
While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in about three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants.
To ensure optimal patient selection and implant technique, Chambersburg Hospital’s interventional cardiology team underwent extensive training on the new device. For more information on the services offered by the interventional cardiologists at Chambersburg Hospital, please click here.